148 related articles for article (PubMed ID: 22494497)
41. Antitumor effect of palmitic acid-conjugated DsiRNA for colon cancer in a mouse subcutaneous tumor model.
Kubo T; Nishimura Y; Hatori Y; Akagi R; Mihara K; Yanagihara K; Seyama T
Chem Biol Drug Des; 2019 Apr; 93(4):570-581. PubMed ID: 30560565
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and properties of double-stranded RNA-bindable oligodiaminogalactose derivatives conjugated with vitamin E.
Iwata R; Nishina K; Yokota T; Wada T
Bioorg Med Chem; 2014 Feb; 22(4):1394-403. PubMed ID: 24462177
[TBL] [Abstract][Full Text] [Related]
43. Targeted gene silencing by small interfering RNA-based knock-down technology.
Zhang J; Hua ZC
Curr Pharm Biotechnol; 2004 Feb; 5(1):1-7. PubMed ID: 14965205
[TBL] [Abstract][Full Text] [Related]
44. Gene silencing mediated by small interfering RNAs in mammalian cells.
Scherr M; Morgan MA; Eder M
Curr Med Chem; 2003 Feb; 10(3):245-56. PubMed ID: 12570711
[TBL] [Abstract][Full Text] [Related]
45. siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract.
Hoerter JA; Krishnan V; Lionberger TA; Walter NG
PLoS One; 2011; 6(5):e20359. PubMed ID: 21647381
[TBL] [Abstract][Full Text] [Related]
46. Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC.
Salomon W; Bulock K; Lapierre J; Pavco P; Woolf T; Kamens J
Nucleic Acids Res; 2010 Jun; 38(11):3771-9. PubMed ID: 20167638
[TBL] [Abstract][Full Text] [Related]
47. Sixteen Different Types of Lipid-Conjugated siRNAs Containing Saturated and Unsaturated Fatty Acids and Exhibiting Enhanced RNAi Potency.
Kubo T; Nishimura Y; Sato Y; Yanagihara K; Seyama T
ACS Chem Biol; 2021 Jan; 16(1):150-164. PubMed ID: 33346648
[TBL] [Abstract][Full Text] [Related]
48. MISSION esiRNA for RNAi screening in mammalian cells.
Theis M; Buchholz F
J Vis Exp; 2010 May; (39):. PubMed ID: 20467416
[TBL] [Abstract][Full Text] [Related]
49. High-pressure sprayed siRNAs influence the efficiency but not the profile of transitive silencing.
Uslu VV; Dalakouras A; Steffens VA; Krczal G; Wassenegger M
Plant J; 2022 Mar; 109(5):1199-1212. PubMed ID: 34882879
[TBL] [Abstract][Full Text] [Related]
50. Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection.
Sano M; Sierant M; Miyagishi M; Nakanishi M; Takagi Y; Sutou S
Nucleic Acids Res; 2008 Oct; 36(18):5812-21. PubMed ID: 18782830
[TBL] [Abstract][Full Text] [Related]
51. Long double-stranded RNA-mediated RNA interference and immunostimulation: long interfering double-stranded RNA as a potent anticancer therapeutics.
Chang CI; Lee TY; Dua P; Kim S; Li CJ; Lee DK
Nucleic Acid Ther; 2011 Jun; 21(3):149-55. PubMed ID: 21749291
[TBL] [Abstract][Full Text] [Related]
52. Topically delivered 22 nt siRNAs enhance RNAi silencing of endogenous genes in two species.
Hendrix B; Zheng W; Bauer MJ; Havecker ER; Mai JT; Hoffer PH; Sanders RA; Eads BD; Caruano-Yzermans A; Taylor DN; Hresko C; Oakes J; Iandolino AB; Bennett MJ; Deikman J
Planta; 2021 Aug; 254(3):60. PubMed ID: 34448043
[TBL] [Abstract][Full Text] [Related]
53. The Effect of Dicer Knockout on RNA Interference Using Various Dicer Substrate Small Interfering RNA (DsiRNA) Structures.
Song MS; Alluin J; Rossi JJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327991
[TBL] [Abstract][Full Text] [Related]
54. Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3' Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs.
Zhou J; Song MS; Jacobi AM; Behlke MA; Wu X; Rossi JJ
Mol Ther Nucleic Acids; 2012 Apr; 1(4):e17. PubMed ID: 23343928
[TBL] [Abstract][Full Text] [Related]
55. Ectopic expression of systemic RNA interference defective protein in embryonic stem cells.
Tsang SY; Moore JC; Huizen RV; Chan CW; Li RA
Biochem Biophys Res Commun; 2007 Jun; 357(2):480-6. PubMed ID: 17434453
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and properties of vitamin E analog-conjugated neomycin for delivery of RNAi drugs to liver cells.
Iwata R; Nakayama F; Hirochi S; Sato K; Piao W; Nishina K; Yokota T; Wada T
Bioorg Med Chem Lett; 2015 Feb; 25(4):815-9. PubMed ID: 25597008
[TBL] [Abstract][Full Text] [Related]
57. What parameters to consider and which software tools to use for target selection and molecular design of small interfering RNAs.
Matveeva O
Methods Mol Biol; 2013; 942():1-16. PubMed ID: 23027043
[TBL] [Abstract][Full Text] [Related]
58. Increased potency and longevity of gene silencing using validated Dicer substrates.
Hefner E; Clark K; Whitman C; Behlke MA; Rose SD; Peek AS; Rubio T
J Biomol Tech; 2008 Sep; 19(4):231-7. PubMed ID: 19137112
[TBL] [Abstract][Full Text] [Related]
59. Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos.
Yang D; Lu H; Erickson JW
Curr Biol; 2000 Oct; 10(19):1191-200. PubMed ID: 11050387
[TBL] [Abstract][Full Text] [Related]
60. Synthetic shRNAs as potent RNAi triggers.
Siolas D; Lerner C; Burchard J; Ge W; Linsley PS; Paddison PJ; Hannon GJ; Cleary MA
Nat Biotechnol; 2005 Feb; 23(2):227-31. PubMed ID: 15619616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
